Literature DB >> 9444073

Serological crossreactivity between Brucella abortus and Yersinia enterocolitica 0:9. III. Specificity of the in vitro antigen-specific gamma interferon test for bovine brucellosis diagnosis in experimentally Yersinia enterocolitica 0:9-infected cattle.

R Kittelberger1, M P Reichel, M A Joyce, C Staak.   

Abstract

The course of immunological reaction in 10 Yersinia enterocolitica 0:9 experimentally-infected heifers was followed using the conventional brucellosis tests complement fixation test (CFT), serum agglutination test (SAT) and brucella card test (BCT), and a recently developed Brucella antigen-specific gamma interferon (IFN-gamma) test. Initially, the animals were exposed orally to 10(10) colony-forming units (CFU) of Y. enterocolitica 0:9. Four weeks later, they were inoculated intravenously with 10(8) CFU of Y. enterocolitica 0:9 cells. After oral inoculation, the response in the conventional brucellosis tests was minimal. Only after intravenous inoculation were CFT and SAT titres and BCT reactions comparable to natural, false positive brucellosis reactors. After oral exposure the Brucellergen-stimulated release of IFN-gamma peaked at values above the cut-off stimulation index of 2.5 in 80% of the heifers. After intravenous inoculation, stimulation indices above 2.5 were present in only 10% of the animals. Two B. abortus infected control cattle showed stimulation indices of 3.1 and 3.4, and a negative control animal exhibited a stimulation index of 1.0. These findings show, in contrast to a previous study, that the Brucellergen-specific IFN-gamma assay cannot be used as a specific and discriminatory test for B. abortus infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444073     DOI: 10.1016/s0378-1135(97)00110-7

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Spatial distribution and risk factors of Brucellosis in Iberian wild ungulates.

Authors:  Pilar M Muñoz; Mariana Boadella; Maricruz Arnal; María J de Miguel; Miguel Revilla; David Martínez; Joaquín Vicente; Pelayo Acevedo; Alvaro Oleaga; Francisco Ruiz-Fons; Clara M Marín; José M Prieto; José de la Fuente; Marta Barral; Montserrat Barberán; Daniel Fernández de Luco; José M Blasco; Christian Gortázar
Journal:  BMC Infect Dis       Date:  2010-03-05       Impact factor: 3.090

2.  Evaluation of a western blot method for the detection of Yersinia antibodies: evidence of serological cross-reactivity between Yersinia outer membrane proteins and Borrelia burgdorferi.

Authors:  Mindy L Rawlins; Cecilia Gerstner; Harry R Hill; Christine M Litwin
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

3.  Enzyme-linked immunosorbent assay to differentiate the antibody responses of animals infected with Brucella species from those of animals infected with Yersinia enterocolitica O9.

Authors:  Janchivdorj Erdenebaatar; Balgan Bayarsaikhan; Masahisa Watarai; Sou-ichi Makino; Toshikazu Shirahata
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

4.  Improving the specificity of immunodiagnosis for porcine brucellosis.

Authors:  R E Thirlwall; N J Commander; S D Brew; S J Cutler; J A McGiven; J A Stack
Journal:  Vet Res Commun       Date:  2007-10-13       Impact factor: 2.459

5.  Human and animal epidemic of Yersinia enterocolitica O:9, 1989-1997, Auvergne, France.

Authors:  F Gourdon; J Beytout; A Reynaud; J P Romaszko; D Perre; P Theodore; H Soubelet; J Sirot
Journal:  Emerg Infect Dis       Date:  1999 Sep-Oct       Impact factor: 6.883

Review 6.  Moving past serology: Diagnostic options without serum.

Authors:  Michael P Reichel; Sasha R Lanyon; Fraser I Hill
Journal:  Vet J       Date:  2016-04-22       Impact factor: 2.688

7.  Comprehensive Identification of Immunodominant Proteins of Brucella abortus and Brucella melitensis Using Antibodies in the Sera from Naturally Infected Hosts.

Authors:  Gamal Wareth; Murat Eravci; Christoph Weise; Uwe Roesler; Falk Melzer; Lisa D Sprague; Heinrich Neubauer; Jayaseelan Murugaiyan
Journal:  Int J Mol Sci       Date:  2016-04-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.